Anaptysbio (ANAB) Gains from Investment Securities (2016 - 2025)
Anaptysbio posted quarterly Gains from Investment Securities of $98000.0 for Q1 2025, down 98.69% year-on-year from $7.5 million in Q1 2024, and down 99.76% on a QoQ basis from $40.2 million in Q4 2024.
Anaptysbio (ANAB) has 9 years of Gains from Investment Securities data on file, last reported at $98000.0 in Q1 2025.
- For the quarter ending Q1 2025, Gains from Investment Securities fell 98.69% year-over-year to $98000.0; the trailing twelve-month figure through Dec 2025 stood at $40.2 million (up 435.54% YoY), and the FY2025 full-year result was $6.9 million, up 13.33% from the prior year.
- Gains from Investment Securities for Q1 2025 stood at $98000.0, down from $40.2 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $40.2 million in Q4 2024 and bottomed at -$24.8 million in Q2 2024.
- The 5-year median for Gains from Investment Securities is -$2.9 million (2021), against an average of $439428.6.
- Peak annual rise in Gains from Investment Securities reached 273.06% in 2024, while the deepest fall reached 468.47% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at -$1.5 million in 2021, then soared by 831.88% to $10.7 million in 2022, then retreated by 18.91% to $8.7 million in 2023, then jumped by 362.24% to $40.2 million in 2024, then tumbled by 99.76% to $98000.0 in 2025.
- The last three Gains from Investment Securities figures came in at $98000.0 (Q1 2025), $40.2 million (Q4 2024), and -$15.4 million (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Anaptysbio | 1.60 Bn | 1.31 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 98,000.00 |
| Mar 31, 2025 | 98,000.00 |
| Dec 31, 2024 | 40.19 Mn |
| Dec 31, 2024 | 40.19 Mn |
| Sep 30, 2024 | -15.41 Mn |
| Sep 30, 2024 | -15.41 Mn |
| Jun 30, 2024 | -24.77 Mn |
| Jun 30, 2024 | -24.77 Mn |
| Mar 31, 2024 | 7.50 Mn |
| Mar 31, 2024 | 7.50 Mn |
| Sep 30, 2023 | 8.69 Mn |
| Sep 30, 2023 | 8.69 Mn |
| Jun 30, 2023 | -4.36 Mn |
| Jun 30, 2023 | -4.36 Mn |
| Mar 31, 2023 | -4.34 Mn |
| Mar 31, 2023 | -4.34 Mn |
| Sep 30, 2022 | 10.72 Mn |
| Sep 30, 2022 | 10.72 Mn |
| Jun 30, 2022 | -5.87 Mn |
| Jun 30, 2022 | -5.87 Mn |
| Mar 31, 2022 | -4.85 Mn |
| Mar 31, 2022 | -4.85 Mn |
| Dec 31, 2021 | -1.47 Mn |
| Dec 31, 2021 | -1.47 Mn |
| Sep 30, 2021 | -20.67 Mn |
| Sep 30, 2021 | -20.67 Mn |
| Jun 30, 2021 | 20.69 Mn |
| Jun 30, 2021 | 20.69 Mn |
| Dec 31, 2019 | -173,000.00 |
| Dec 31, 2019 | -173,000.00 |
| Sep 30, 2019 | -171,000.00 |
| Sep 30, 2019 | -171,000.00 |
| Jun 30, 2019 | -168,000.00 |
| Jun 30, 2019 | -168,000.00 |
| Mar 31, 2019 | -164,000.00 |
| Mar 31, 2019 | -164,000.00 |
| Dec 31, 2018 | -165,000.00 |
| Dec 31, 2018 | -165,000.00 |
| Mar 31, 2018 | -156,000.00 |
| Mar 31, 2018 | -156,000.00 |
| Dec 31, 2017 | 1.83 Mn |
| Dec 31, 2017 | 1.83 Mn |
| Mar 31, 2017 | 1.37 Mn |
| Mar 31, 2017 | 1.37 Mn |
| Dec 31, 2016 | 1.09 Mn |
| Dec 31, 2016 | 1.09 Mn |
| Sep 30, 2016 | 47,000.00 |
| Sep 30, 2016 | 47,000.00 |
| Jun 30, 2016 | -3,000.00 |
| Jun 30, 2016 | -3,000.00 |
| Mar 31, 2016 | -22,000.00 |
| Mar 31, 2016 | -22,000.00 |